Asthma
FDA Approves Merck's DULERA(R) mometasone furoate and formoterol fumarate dihydrate Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older
Published in Medical Letter on the CDC and FDA, July 11th, 2010
Merck announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate). The approval of DULERA is based, in part, on Phase III studies that evaluated the safety and efficacy of DULERA in patients 12 years of age and older with persistent asthma.
"Despite the advances made in the treatment of asthma in recent years,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Diabetes
New findings reported from I.B. Ahluwalia and co-authors describe advances in diabetes - Homeland Security and Emergency Management
New homeland security and emergency management study findings recently were reported by researchers at National Institute for Occupational Safety and Health - U.S. Food and Drug Administration
P&G Voluntarily Recalls 4 Hour Decongestant Nasal Spray in the United States - Ventral Hernia
PolyTouch Medical Ltd. Receives FDA Clearance to Commercialize PatchAssist - an Innovative Surgical Instrument Intended to Facilitate the Delivery of Soft Tissue Prosthetics During the Laparoscopic Repair of Soft Tissue Defects - CDC and FDA
Reports from National Center for Chronic Disease Prevention and Health Promotion highlight recent research in CDC and FDA - Public Health
Study results from G.H. Payne et al provide new insights into public health - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
